Procter & Gamble has ended its collaboration with ARYx Therapeutics for development and commercialization of 5-HT4 agonist ATI-7505 for chronic constipation and functional dyspepsia.
Filed under: Uncategorized | Tagged: 5-HT4, 5HT4, agonist, ARYx, ATI-7505, ATI7505, Licensing, Procter & Gamble | Leave a Comment »
ARYx Therapeutic’s 5HT4 agonist ATI-7505 has shown a favorable QT profile. The drug is in Phase II trials for chronic constipation and functional dyspepsia.
Filed under: gpcr | Tagged: 5-HT4, 5HT4, agonist, ARYx, ATI-7505, ATI7505, Procter & Gamble | Leave a Comment »
Titan Pharmaceutical’s cell based cell-based therapy for the potential treatment of moderate to advanced Parkinson’s disease has not met endpoints in a Phase IIb trial. The human retinal pigment epithelium (hRPE) cell-based therapeutic is delivered by stereotaxic injection into the brain and produces dopamine specifically to sites deficient in dopamine
Filed under: Uncategorized | Tagged: agonist, Cell Therapy, Dopamine, phase II, Phase IIb, Spheramine, Tital | Leave a Comment »
Sciele Pharma has signed an agreement to license Addrenex Pharmaceuticals alpha 2 agonist ADX415 for the Treatment of Hypertension.
Filed under: gpcr | Tagged: Addrenex, ADX-415, ADX415, agonist, Alpha 2 Adrenoceptor, Licensing, Sciele | Leave a Comment »
